The global engineered T cells market was valued at $9,668.0 million in 2020, and is projected to reach $149,650.6 million by 2030, registering a CAGR of 32.5% from 2021 to 2030.
T cell is a type of white blood cell, which plays an important role in cell-medicated immunity. Engineered T cells are genetically modified T cells, specifically altered for therapeutic actions against autoimmune diseases and various types of cancers. The engineered T cells are delivered into patient’s body to reduce toxicity levels and restrict antigen escape (inability of immune system to respond to an infectious agent) for elimination of cancerous cells.
The increase in prevalence of cancer globally drives the growth of engineered T cells market. For instance, according to World Health Organization (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. In addition, surge in geriatric population propels the growth of engineered T cells market. The R&D in the T cell technology by manufacturers and researchers contributes in the growth of market. Furthermore, initiatives taken by governments and private organization to treat and improve the lifestyle of cancer patients boost the market growth. The rise in number of hospitals and well-developed healthcare infrastructure further contributes in market growth.
In addition, increase in advancement in T cell therapy and new product launch contribute in the growth of the engineered T cells market. However, the high cost of T cell technology is expected to limit the growth of market.
The engineered T cells market is segmented on the basis of type, application, end user, and region. By Type, the market is mainly categorized into chimeric antigen receptor (CAR) modified T cells, T cells receptor (TCR) modified T cells, and tumor infiltrating lymphocytes. By application, it is categorized into lung cancer, breast cancer, colorectal cancer, melanoma, leukemia and others application. Based on end user, it is divided into hospital, cancer research center, and clinic. By Region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include Amgen Inc, Athenex Inc, Bellicum Pharmaceuticals, Inc., Bristol-Myers Squibb, Eli Lilly And Company, Gilead Sciences, Inc., Novartis Ag, Oxford Biomedica Plc, Pfizer Inc., and Precision Biosciences Inc.
T cell is a type of white blood cell, which plays an important role in cell-medicated immunity. Engineered T cells are genetically modified T cells, specifically altered for therapeutic actions against autoimmune diseases and various types of cancers. The engineered T cells are delivered into patient’s body to reduce toxicity levels and restrict antigen escape (inability of immune system to respond to an infectious agent) for elimination of cancerous cells.
The increase in prevalence of cancer globally drives the growth of engineered T cells market. For instance, according to World Health Organization (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. In addition, surge in geriatric population propels the growth of engineered T cells market. The R&D in the T cell technology by manufacturers and researchers contributes in the growth of market. Furthermore, initiatives taken by governments and private organization to treat and improve the lifestyle of cancer patients boost the market growth. The rise in number of hospitals and well-developed healthcare infrastructure further contributes in market growth.
In addition, increase in advancement in T cell therapy and new product launch contribute in the growth of the engineered T cells market. However, the high cost of T cell technology is expected to limit the growth of market.
The engineered T cells market is segmented on the basis of type, application, end user, and region. By Type, the market is mainly categorized into chimeric antigen receptor (CAR) modified T cells, T cells receptor (TCR) modified T cells, and tumor infiltrating lymphocytes. By application, it is categorized into lung cancer, breast cancer, colorectal cancer, melanoma, leukemia and others application. Based on end user, it is divided into hospital, cancer research center, and clinic. By Region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include Amgen Inc, Athenex Inc, Bellicum Pharmaceuticals, Inc., Bristol-Myers Squibb, Eli Lilly And Company, Gilead Sciences, Inc., Novartis Ag, Oxford Biomedica Plc, Pfizer Inc., and Precision Biosciences Inc.
KEY BENEFITS FOR STAKEHOLDERS
- The report provides an in-depth analysis of the global Engineered T cells market size along with the current trends and future estimations to elucidate the imminent investment pockets
- It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market
- A comprehensive analysis of the region assists to understand the regional market and facilitate strategic business planning and determine prevailing opportunities
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global Engineered T cells market growth
KEY MARKET SEGMENTS
By Type
- Chimeric Antigen Receptor (Car) Modified T Cells
- T Cells Receptor (Tcr) Modified T Cells
- Tumor Infiltrating Lymphocytes
By application
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Leukemia
- Others Application
By End User
- Hospitals
- Cancer Research Centers
- Clinics
By Region
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- Australia
- India
- South Korea
- Taiwan
- Rest of Asia Pacific
- LAMEA
- Brazil
- Turkey
- Saudi Arabia
- South Africa
- Rest of LAMEA
KEY MARKET PLAYERS
- Amgen Inc
- Athenex Inc
- Bellicum Pharmaceuticals, Inc
- Bristol-Myers Squibb
- Eli Lilly And Company
- Gilead Sciences, Inc
- Novartis Ag
- Oxford Biomedica Plc
- Pfizer Inc
- Precision Biosciences Inc
Table of Contents
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Landscape
Chapter 4: Engineered T Cells Market, by Type
Chapter 5: Engineered T Cells Market, by Application
Chapter 6: Engineered T Cells Market, by End-user
Chapter 7: Engineered T Cells Market, by Region
Chapter 8: Company Profiles
List of Tables
List of Figures
Executive Summary
According to a new report titled, “Engineered T Cells Market by Type, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2021–2030, the global engineered T cells market was valued at $9,668.0 million in 2020, and is projected to reach $149,650.6 million by 2030, registering a CAGR of 32.5% from 2021 to 2030.Engineered T cells, also known as specifically modified T cells, are designed for the treatment of autoimmune diseases, primary immune deficiencies, and cancer. After administration of engineered T cells product, it enables reduction of toxicities and inhibits antigen escape (inability of immune system to respond to an infectious agent). The engineered T cells assist immune system to overcome the immunosuppressive tumor microenvironments and target cancer cells for effective treatment
Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T cells are changed in the laboratory so they bind to cancer cells and kill them. The CAR T-cell therapy is used to treat cancers such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL) in pediatric and young adult patients up to age 25.
Factors that drive the growth of the engineered T cells market include the rise in number of hospitals, increase in prevalence of cancer, and surge in number of geriatric population. For instance, as per the population reference bureau report, “Aging in the U.S.,” dated, July, 2019, number of Americans aged 65 and older is projected to increase more than double from 52 million in 2018 to over 95 million by 2060, and is expected to rise to around 23% from 16%. Furthermore, increase in R&D activity in T cell technology contributes in the growth of the engineered T cells market.
The Engineered T cells market is segmented on the basis of type, application, end user, and region. By type, the market is divided into chimeric antigen receptor (CAR) modified T cells, T cells receptor (TCR) modified T cells, and tumor infiltrating lymphocytes. The chimeric antigen receptor (CAR) modified T cells segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to the advancement in car T cell technology.
Based on application, the market is categorized into lung cancer, breast cancer, colorectal cancer, melanoma, and leukemia. The lung cancer segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to surge in prevalence of lung cancer. By end user, the market is divided into hospitals, cancer research centers, and clinics. The hospitals segment dominated the market in 2020, and this trend is expected to continue during the forecast period, due to increase in number of cancer hospitals.
North America accounted for a majority of the global Engineered T cells market is projected to tank $149.65 Bn by 2030. The profiles and growth strategies of the key players are thoroughly analyzed in the study.share in 2020, and is anticipated to remain dominant during the forecast period. Asia-Pacific is anticipated to witness lucrative growth, owing to the prevalence of cancer in region.
What is the Impact of COVID-19 Pandemic on Engineered T Cells Market?
The COVID-19 outbreak is anticipated to have a negative impact on growth of the global engineered T cells market. The increased prevalence of viral infection has delayed the R&D activities for diseases; thereby, having a minimal negative impact on the market. The COVID-19 virus has serious and life-threatening impact on seriously ill patients. However, a huge number of clinics and hospitals across the globe were restructured to increase hospital capacity to provide better healthcare facility.
Key Findings Of Study
- On the basis of type, the chimeric antigen receptor (CAR) modified T cells segment was the highest contributor to the market in 2020
- Based on of application, the lung cancer segment was the highest contributor to the market in 2020
- Depending on end user, hospital segment dominated the market in 2020
- On the basis of region, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period
Companies Mentioned
- Amgen Inc
- AthenexInc
- Bellicum Pharmaceuticals, Inc.
- Bristol-Myers Squibb
- Eli Lilly And Company
- Gilead Sciences, Inc.
- Novartis AG
- Oxford BiomedicaPlc
- Pfizer Inc.
- Precision Biosciences Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 227 |
| Published | February 2022 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 9668 million |
| Forecasted Market Value ( USD | $ 149650.6 million |
| Compound Annual Growth Rate | 31.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
